Glucagon-like peptide-1 and its class B G protein-coupled receptors

a long march to therapeutic successes

Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng, Ming-Wei Wang

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The glucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three major tissues in humans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a two domain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable non peptidic GLP-1R agonists have been hampered, small-molecule modulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.
Original languageEnglish
Pages (from-to)954-1013
Number of pages60
JournalPharmacological Reviews
Volume68
Issue number4
DOIs
Publication statusPublished - 1 Oct 2016

Cite this

de Graaf, Chris ; Donnelly, Dan ; Wootten, Denise ; Lau, Jesper ; Sexton, Patrick M. ; Miller, Laurence J. ; Ahn, Jung-Mo ; Liao, Jiayu ; Fletcher, Madeleine M. ; Yang, Dehua ; Brown, Alastair J. H. ; Zhou, Caihong ; Deng, Jiejie ; Wang, Ming-Wei. / Glucagon-like peptide-1 and its class B G protein-coupled receptors : a long march to therapeutic successes. In: Pharmacological Reviews. 2016 ; Vol. 68, No. 4. pp. 954-1013.
@article{a7936d2e2460423c84bc4c60cf5717bf,
title = "Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes",
abstract = "The glucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three major tissues in humans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a two domain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable non peptidic GLP-1R agonists have been hampered, small-molecule modulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.",
author = "{de Graaf}, Chris and Dan Donnelly and Denise Wootten and Jesper Lau and Sexton, {Patrick M.} and Miller, {Laurence J.} and Jung-Mo Ahn and Jiayu Liao and Fletcher, {Madeleine M.} and Dehua Yang and Brown, {Alastair J. H.} and Caihong Zhou and Jiejie Deng and Ming-Wei Wang",
year = "2016",
month = "10",
day = "1",
doi = "10.1124/pr.115.011395",
language = "English",
volume = "68",
pages = "954--1013",
journal = "Pharmacological Reviews",
issn = "1521-0081",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

de Graaf, C, Donnelly, D, Wootten, D, Lau, J, Sexton, PM, Miller, LJ, Ahn, J-M, Liao, J, Fletcher, MM, Yang, D, Brown, AJH, Zhou, C, Deng, J & Wang, M-W 2016, 'Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes', Pharmacological Reviews, vol. 68, no. 4, pp. 954-1013. https://doi.org/10.1124/pr.115.011395

Glucagon-like peptide-1 and its class B G protein-coupled receptors : a long march to therapeutic successes. / de Graaf, Chris; Donnelly, Dan; Wootten, Denise; Lau, Jesper; Sexton, Patrick M.; Miller, Laurence J.; Ahn, Jung-Mo; Liao, Jiayu; Fletcher, Madeleine M.; Yang, Dehua; Brown, Alastair J. H.; Zhou, Caihong; Deng, Jiejie; Wang, Ming-Wei.

In: Pharmacological Reviews, Vol. 68, No. 4, 01.10.2016, p. 954-1013.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Glucagon-like peptide-1 and its class B G protein-coupled receptors

T2 - a long march to therapeutic successes

AU - de Graaf, Chris

AU - Donnelly, Dan

AU - Wootten, Denise

AU - Lau, Jesper

AU - Sexton, Patrick M.

AU - Miller, Laurence J.

AU - Ahn, Jung-Mo

AU - Liao, Jiayu

AU - Fletcher, Madeleine M.

AU - Yang, Dehua

AU - Brown, Alastair J. H.

AU - Zhou, Caihong

AU - Deng, Jiejie

AU - Wang, Ming-Wei

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The glucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three major tissues in humans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a two domain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable non peptidic GLP-1R agonists have been hampered, small-molecule modulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

AB - The glucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three major tissues in humans,enteroendocrine L cells in the distal intestine, a cells in the pancreas, and the central nervous system, which exerts important actions useful in the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake. Peptidic analogs of GLP-1 have been successfully developed with enhanced bioavailability and pharmacological activity. Physiologic and biochemical studies with truncated, chimeric, and mutated peptides and GLP-1R variants, together with ligand-bound crystal structures of the extracellular domain and the first three-dimensional structures of the 7-helical transmembrane domain of class B GPCRs, have provided the basis for a two domain-binding mechanism of GLP-1 with its cognate receptor. Although efforts in discovering therapeutically viable non peptidic GLP-1R agonists have been hampered, small-molecule modulators offer complementary chemical tools to peptide analogs to investigate ligand-directed biased cellular signaling of GLP-1R. The integrated pharmacological and structural information of different GLP-1 analogs and homologous receptors give new insights into the molecular determinants of GLP-1R ligand selectivity and functional activity, thereby providing novel opportunities in the design and development of more efficacious agents to treat metabolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=84988028207&partnerID=8YFLogxK

U2 - 10.1124/pr.115.011395

DO - 10.1124/pr.115.011395

M3 - Article

VL - 68

SP - 954

EP - 1013

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 1521-0081

IS - 4

ER -